IVAN ROSAS to Treatment Outcome
This is a "connection" page, showing publications IVAN ROSAS has written about Treatment Outcome.
Connection Strength
0.165
-
A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. Chest. 2018 01; 153(1):94-104.
Score: 0.033
-
Association of Donor and Recipient Telomere Length with Clinical Outcomes following Lung Transplantation. PLoS One. 2016; 11(9):e0162409.
Score: 0.031
-
Update in diffuse parenchymal lung disease, 2013. Am J Respir Crit Care Med. 2015 Feb 01; 191(3):270-4.
Score: 0.028
-
A Phase IIb Randomized Clinical Study of an Anti-av?6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022 11 01; 206(9):1128-1139.
Score: 0.012
-
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med. 2023 01; 11(1):87-96.
Score: 0.012
-
Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes. Sci Rep. 2019 10 15; 9(1):14802.
Score: 0.010
-
Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review. J Rheumatol. 2018 06; 45(6):841-850.
Score: 0.009
-
The Presence of Pretransplant HLA Antibodies Does Not Impact the Development of Chronic Lung Allograft Dysfunction or CLAD-Related Death. Transplantation. 2017 09; 101(9):2207-2212.
Score: 0.008
-
Comparison of extracorporeal photopheresis and alemtuzumab for the treatment of chronic lung allograft dysfunction. J Heart Lung Transplant. 2018 03; 37(3):340-348.
Score: 0.008
-
Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial. Chest. 2017 06; 151(6):1302-1310.
Score: 0.008
-
Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. Eur Respir J. 2015 Sep; 46(3):783-94.
Score: 0.007